Laxmi Dental Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹977 Cr
- P/E
- 28.08
- ROE
- 14.83%
- PEG
- 0.22
- Price to sales
- 3.40
- Debt to equity
- 0.05
- 52W high / low
- ₹342 / ₹158
- Sales growth (5Y)
- 24.69%
- EBITDA margin
- 15.98%
- Net profit margin
- 12.03%
- Promoter holding
- 41.80%
- Sales (last year)
- ₹287 Cr
Incorporated in 2004, Laxmi Dental is an integrated dental products company offering a comprehensive portfolio of Dental Products[1]
Guidance scorecard · Q1 FY27 call
What Laxmi Dental Ltd's management guided
and where it ranks in Healthcare Equipment & Supplies
Healthcare Equipment & Supplies
RevenueQ1 FY27 call
10–20%- Laxmi Dental aims to outperform the industry CAGR in the aligner business, targeting exponential growth beyond the current ~30% CAGR through branding, education, and marketing initiatives.
- The company expects strong growth momentum in aligners supported by training, education, and technology like iScope for at-home monitoring.
- Domestic dental lab business showed 12% y-o-y growth and the company expects acceleration in growth in upcoming quarters Q2, Q3, and Q4.
- Scanner deployment is planned at 800-1,000 units for the current financial year, with adoption expected to gradually drive growth over the next quarters.
2 more points from Laxmi Dental Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Laxmi Dental Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Laxmi Dental plans to invest in new machinery during FY27 to modernize and expand manufacturing capacity, supporting long-term growth and improving operational efficiencies.
- The company has executed a letter of intent to acquire new land in Palghar, Maharashtra, aiming to transition from leased premises to an owned facility to enhance workflow efficiency, cost control, and future scalability.
- Plans to let go of two rented factory facilities and move operations to the new facility to eliminate rental costs, with a phased transition to avoid disruptions.
2 more points from Laxmi Dental Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Laxmi Dental Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Rising- The focus is on strong Q1 FY27 results with highest-ever quarterly revenue, good growth in domestic and international markets, and strategic initiatives.
- Management emphasizes controlling performance factors, margin stability, and growth in dental lab and aligner segments.
- Scanner deployment expected to be 800-1000 units in the current financial year, indicating ongoing demand pipeline.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Equipment & Supplies companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Flat | ₹627 Cr | 21.4 | |
| 2 | 40%+ | Flat | ₹147 Cr | 16.8 | |
| 3 | Q-Line Biotech | 20–40% | Up 2%+ | ₹1,467 Cr | 25.9 |
| 4 | 20–40% | Flat | ₹18,144 Cr | 83.6 | |
| 5 | 20–40% | Flat | ₹173 Cr | 35.0 | |
| 6 | 10–20% | Up 2%+ | ₹170 Cr | 18.8 |
Sign up free to see every company in the sector ranking and track Laxmi Dental Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies rankingFinancials of Laxmi Dental Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Laxmi Dental Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 48 | 55 | 60 | 57 | 62 | 61 | 66 | 72 | 66 | 74 |
| Expenses + | 44 | 43 | 46 | 48 | 52 | 51 | 54 | 61 | 59 | 60 |
| Operating Profit | 4 | 12 | 14 | 9 | 10 | 10 | 12 | 11 | 7 | 14 |
| OPM % | 8% | 21% | 23% | 15% | 16% | 16% | 18% | 15% | 11% | 18% |
| Other Income + | -0 | -0 | 6 | 1 | 1 | 2 | 2 | 2 | -4 | 2 |
| Interest | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Profit before tax | -1 | 7 | 16 | 5 | 5 | 6 | 10 | 9 | -1 | 11 |
| Tax % | -140% | 16% | 11% | 23% | 23% | 41% | 24% | 20% | -175% | 4% |
| Net Profit + | 2 | 8 | 17 | 6 | 5 | 4 | 8 | 9 | 2 | 10 |
| EPS in Rs | 74.05 | 243.91 | 6.04 | 2.12 | 0.93 | 0.78 | 1.53 | 1.55 | 0.36 | 1.83 |
Financials of Laxmi Dental Ltd
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales + | 150 | 92 | 137 | 162 | 194 | 239 | 278 |
| Expenses + | 146 | 88 | 130 | 152 | 169 | 196 | 234 |
| Operating Profit | 3 | 4 | 7 | 9 | 24 | 43 | 43 |
| OPM % | 2% | 5% | 5% | 6% | 13% | 18% | 16% |
| Other Income + | 2 | 0 | -10 | 2 | 0 | 10 | 3 |
| Interest | 3 | 3 | 4 | 4 | 6 | 6 | 1 |
| Depreciation | 7 | 6 | 8 | 11 | 12 | 15 | 16 |
| Profit before tax | -4 | -4 | -16 | -5 | 7 | 31 | 29 |
| Tax % | 5% | 8% | 15% | 4% | -136% | 21% | 9% |
| Net Profit + | -5 | -5 | -19 | -4 | 25 | 32 | 29 |
| EPS in Rs | -154.92 | -156.22 | -596.62 | -128.94 | 804.81 | 5.78 | 5.27 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Laxmi Dental Ltd
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | 11 | 11 |
| Reserves | 37 | 33 | 9 | 6 | 31 | 198 | 232 |
| Borrowings + | 37 | 39 | 50 | 50 | 61 | 20 | 13 |
| Other Liabilities + | 31 | 34 | 43 | 40 | 46 | 60 | 38 |
| Total Liabilities | 106 | 106 | 103 | 97 | 139 | 288 | 294 |
| Fixed Assets + | 39 | 42 | 40 | 40 | 46 | 51 | 63 |
| CWIP | 0 | 7 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 6 | 10 | 27 |
| Other Assets + | 66 | 56 | 63 | 56 | 87 | 227 | 204 |
| Total Assets | 106 | 106 | 103 | 97 | 139 | 288 | 294 |
Financials of Laxmi Dental Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 12 | 10 | -2 | 14 | 8 | 44 | -5 |
| Cash from Investing Activity + | -18 | -9 | 3 | -10 | -11 | -29 | -80 |
| Cash from Financing Activity + | 6 | -0 | -4 | -1 | -3 | 111 | -18 |
| Net Cash Flow | 0 | 0 | -3 | 3 | -5 | 125 | -102 |
| Free Cash Flow | -5 | 0 | -0 | 5 | -5 | 28 | -23 |
| CFO/OP | 357% | 226% | -30% | 157% | 38% | 109% | 4% |
Financials of Laxmi Dental Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 64 | 54 | 46 | 47 | 56 | 60 |
| Inventory Days | 186 | 305 | 272 | 212 | 397 | 97 | |
| Days Payable | 197 | 273 | 245 | 197 | 585 | 47 | |
| Cash Conversion Cycle | 54 | 96 | 81 | 61 | 47 | -132 | 109 |
| Working Capital Days | 13 | 3 | -3 | -13 | 0 | 37 | 195 |
| ROCE % | 3% | -1% | 1% | 18% | 19% | 15% |
Guidance history
How Laxmi Dental Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | Rising |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY26 call → | 20–40% | Flat | — | — | — |
| Q2 FY26 call → | 20–40% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
12 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −43.9% | 9% |
| Last 6 months | −10.8% | 37% |
| Last 3 months | −16.5% | 29% |
The price is 65.5% below its all-time high of ₹514.1 (24 Jan 2025). Stocks more than 20% below their peak have their score halved, so 24 became 12.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Laxmi Dental Ltd: 0.4 × 9 + 0.4 × 37 + 0.2 × 29 = 24, halved to 12 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Laxmi Dental Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
- Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
- Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
- Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec